EGFR and lung adenocarcinoma: EGFR-tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and afatinib, have shown promising efficacy (60–80% response rate and 9–13 months of progression-free survival) in treating advanced lung adenocarcinoma harboring L858R or exon 19 deletion mutations in clinical trials [7,8,9].